Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Long-term safety and disease control with ruxolitinib cream in atopic dermatitis: Results from two phase 3 studies
Kim Papp, Jacek C. Szepietowski, Leon Kircik, et al.
Journal of the American Academy of Dermatology (2022) Vol. 88, Iss. 5, pp. 1008-1016
Closed Access | Times Cited: 52

Showing 1-25 of 52 citing articles:

Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer
Xue Chen, Qinfan Yao, Xinyu Gu, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 214
Atopic dermatitis (eczema) guidelines: 2023 American Academy of Allergy, Asthma and Immunology/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters GRADE– and Institute of Medicine–based recommendations
Derek K. Chu, Lynda C. Schneider, Rachel Netahe Asiniwasis, et al.
Annals of Allergy Asthma & Immunology (2023) Vol. 132, Iss. 3, pp. 274-312
Open Access | Times Cited: 99
JAK-STAT pathway inhibitors in dermatology
Hélio Amante Miot, Paulo Ricardo Criado, Caio César Silva de Castro, et al.
Anais Brasileiros de Dermatologia (2023) Vol. 98, Iss. 5, pp. 656-677
Open Access | Times Cited: 45
New and Upcoming Topical Treatments for Atopic Dermatitis: A Review of the Literature
Nikolaos Sideris, Eleni Paschou, K. Bakirtzi, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 17, pp. 4974-4974
Open Access | Times Cited: 39
Real-World Use of Ruxolitinib Cream: Safety Analysis at 1 Year
Wilson Hu, Michele Thornton, Robert A. Livingston
American Journal of Clinical Dermatology (2024) Vol. 25, Iss. 2, pp. 327-332
Open Access | Times Cited: 9
Topical anti-inflammatory treatments for eczema: network meta-analysis
S. Lax, Eleanor Van Vogt, Bridget Candy, et al.
Cochrane library (2024) Vol. 2024, Iss. 8
Closed Access | Times Cited: 9
A Maximum-Use Trial of Ruxolitinib Cream in Children Aged 2–11 Years with Moderate to Severe Atopic Dermatitis
Linda Stein Gold, Robert Bissonnette, Seth Forman, et al.
American Journal of Clinical Dermatology (2025)
Open Access | Times Cited: 1
Topical ruxolitinib: A new treatment for vitiligo
Gianluca Tavoletti, Gianluca Avallone, Claudio Conforti, et al.
Journal of the European Academy of Dermatology and Venereology (2023) Vol. 37, Iss. 11, pp. 2222-2230
Open Access | Times Cited: 21
Biologics Versus JAK Inhibitors. Part II: Risk of Infections. A Narrative Review
Miguel Mansilla‐Polo, D. Morgado‐Carrasco
Dermatology and Therapy (2024) Vol. 14, Iss. 8, pp. 1983-2038
Open Access | Times Cited: 8
Efficacy, Safety, and Long-Term Disease Control of Ruxolitinib Cream Among Adolescents with Atopic Dermatitis: Pooled Results from Two Randomized Phase 3 Studies
Lawrence F. Eichenfield, Eric L. Simpson, Kim Papp, et al.
American Journal of Clinical Dermatology (2024) Vol. 25, Iss. 4, pp. 669-683
Open Access | Times Cited: 7
Impact of Crisaborole in Treatment-Experienced Patients With Mild-to-Moderate Atopic Dermatitis
Linda Stein Gold, Wynnis L. Tom, Vivian Y. Shi, et al.
Dermatitis (2024) Vol. 35, Iss. 1, pp. 84-91
Open Access | Times Cited: 5
Novel Therapeutic Targets for the Treatment of Atopic Dermatitis
Gaku Tsuji, Kazuhiko Yamamura, Koji Kawamura, et al.
Biomedicines (2023) Vol. 11, Iss. 5, pp. 1303-1303
Open Access | Times Cited: 12
Satisfaction with Control of Mild to Moderate Atopic Dermatitis with Ruxolitinib Cream: US Physician and Patient Perspectives
Lawrence F. Eichenfield, J. Z. Liu, Simran Marwaha, et al.
Dermatology and Therapy (2024) Vol. 14, Iss. 3, pp. 685-696
Open Access | Times Cited: 4
Therapeutic efficacy and safety of topical ruxolitinib in mild-to-moderate atopic dermatitis: a systematic review
Cíntia Bassani, Grazia Pertile, Sérgio Souza da Cunha, et al.
Deleted Journal (2025), pp. 100032-100032
Open Access
Atopic Dermatitis Treatments Before and After Initiation of Ruxolitinib Cream: 6-Month Follow-Up Analysis of a US Payer Claims Database
J. Z. Liu, Karishma Desai, Chia‐Chen Teng, et al.
ClinicoEconomics and Outcomes Research (2025) Vol. Volume 17, pp. 69-77
Open Access
What Does Long-Term Control in Atopic Dermatitis Look Like?
Shanthi Narla, Zelma C. Chiesa Fuxench, Katrina Abuabara, et al.
Dermatitis (2025)
Closed Access
Canadian Consensus Guidelines for the Management of Atopic Dermatitis with Topical Therapies
Melinda Gooderham, Chih-ho Hong, Charles Lynde, et al.
Dermatology and Therapy (2025)
Open Access
Innovations and Emerging Therapies in Atopic Dermatitis Part 2
Robyn Okereke, Eric L. Simpson
Current Treatment Options in Allergy (2025) Vol. 12, Iss. 1
Closed Access
Ruxolitinib Cream 1.5%: A Review in Mild to Moderate Atopic Dermatitis
Sheridan M. Hoy
American Journal of Clinical Dermatology (2022) Vol. 24, Iss. 1, pp. 143-151
Open Access | Times Cited: 17
The Future of Atopic Dermatitis Treatment
Katie Lovell, Nupur Patel, Saroja Rao, et al.
Advances in experimental medicine and biology (2024), pp. 227-244
Closed Access | Times Cited: 3
Biologics Versus JAK Inhibitors. Part I: Cancer Risk. A Narrative Review
Miguel Mansilla‐Polo, D. Morgado‐Carrasco
Dermatology and Therapy (2024) Vol. 14, Iss. 6, pp. 1389-1442
Open Access | Times Cited: 3
Maternal Janus kinase inhibitor use is associated with increased risk of aborted pregnancy: a systematic review and meta-analysis
Ajay S. Dulai, Koushik Tripathy, Emi M. Murase, et al.
British Journal of Dermatology (2025)
Closed Access
Short-term efficacy and safety of biologics and Janus kinase inhibitors for patients with atopic dermatitis: A systematic review and meta-analysis
Qianyu Chen, Lian Cui, Yifan Hu, et al.
Heliyon (2023) Vol. 9, Iss. 11, pp. e22014-e22014
Open Access | Times Cited: 8
Ruxolitinib cream monotherapy demonstrates rapid improvement in the extent and signs of mild to moderate atopic dermatitis across head and neck and other anatomic regions in adolescents and adults: pooled results from 2 phase 3 studies
Eric L. Simpson, Robert Bissonnette, Zelma C. Chiesa Fuxench, et al.
Journal of Dermatological Treatment (2024) Vol. 35, Iss. 1
Open Access | Times Cited: 3
Application of JAK inhibitors in paradoxical reaction through immune-related dermatoses
Yaxin Zhang, Guan Jiang
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top